CJC-1295 alternatives.
10 compounds compared to CJC-1295, ranked by published evidence tier and regulatory status, not by what's marketed hardest.
Half the people searching for CJC-1295 alternatives are really trying to escape a naming problem. The label covers two different molecules: the version with a Drug Affinity Complex that binds albumin and acts for a long time, and the version without it, sold as modified GRF 1-29, which does not. Neither has ever been approved by the FDA or any major regulator, development did not complete, and both are sold only as research chemicals and prohibited in sport by WADA as GHRH analogs. If what you want is a GHRH analog with regulatory standing, the field narrows to tesamorelin and to sermorelin's discontinued approval, not to another research peptide.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), based on the first 29 amino acids of human GHRH (GRF 1-29) with several amino-acid substitutions that resist enzymatic degradation.
- 01TesamorelinA tierFDA-approvedEgrifta
Acts through the ghrh signalling pathway, like CJC-1295. FDA-approved.
- 02SermorelinC tierResearch / preclinical
Acts through the ghrh signalling pathway, like CJC-1295. Research / preclinical.
- 03CJC-1295 DACF tierResearch / preclinical
Acts through the ghrh signalling pathway, like CJC-1295. Research / preclinical.
- 04Mod-GRF (1-29)F tierResearch / preclinicalCJC-1295 no-DAC
Acts through the ghrh signalling pathway, like CJC-1295. Research / preclinical.
- 05
- 06
- 07GHRP-1D tierResearch / preclinicalgrowth hormone-releasing peptide-1
Same category: growth hormone. Research / preclinical.
- 08GHRP-2D tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 09GHRP-6D tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 10HexarelinD tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
An “alternative” here means a compound that shares CJC-1295's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.
PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.